Supriya Lifescience
NSE: SUPRIYA · ISIN INE07RO01027 · Healthcare
₹635.95−15.00 (−2.30%)
Monday 9 November, 12:47 IST. Delayed. Source: Yahoo Finance.
Price chart
₹635.95 −15.00 (−2.30%) today
The day
- Previous close
- ₹650.95
- Open
- ₹639.45
- Day high
- ₹661.75
- Day low
- ₹598.05
Listed on NSE since 28 December 2021.
Key numbers
- Market value
- ₹5,239.03 Cr
- P/E (trailing)
- 26.41
- EPS (trailing)
- ₹24.65
- Price to book
- 4.37
- Dividend yield
- 0.14%
- Debt to equity
- 0.00
- Profit margin
- 22.7%
- Beta
- 0.67
- Volume today
- 25.69 L
- Average volume
- 3.18 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹451.02 Cr | ₹89.86 Cr |
| FY24 | ₹557.41 Cr | ₹119.11 Cr |
| FY25 | ₹679.56 Cr | ₹187.96 Cr |
| FY26 | ₹802.37 Cr | ₹209.12 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹206 Cr | ₹29 Cr | −42.0% |
| Q1 FY27Apr–Jun 2026 | ₹190 Cr | ₹24 Cr | −30.9% |
| Q4 FY26Jan–Mar 2026Audited | ₹277 Cr | ₹74 Cr | +47.3% |
| Q3 FY26Oct–Dec 2025 | ₹206 Cr | ₹50 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹200 Cr | ₹50 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹145 Cr | ₹35 Cr | – |
Source: Supriya Lifescience’s results filed with NSE, standalone (the company alone). Net profit is the share of Supriya Lifescience’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹741 Cr | ₹719 Cr |
| Investments | ₹107 Cr | ₹99 Cr |
| Inventories | ₹265 Cr | ₹160 Cr |
| Owed by customers | ₹126 Cr | ₹219 Cr |
| Cash and equivalents | ₹41 Cr | ₹38 Cr |
| Total assets | ₹1,422 Cr | ₹1,357 Cr |
| Borrowings | ₹0 | ₹0 |
| Total liabilities | ₹179 Cr | ₹159 Cr |
| Shareholders’ equity | ₹1,243 Cr | ₹1,198 Cr |
Source: Supriya Lifescience’s half-yearly statements of assets and liabilities filed with NSE, standalone. Companies file these every September and March.
About Supriya Lifescience
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals in India and internationally. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides finished formulation products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it develops drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.
- Industry
- Biotechnology
- Based in
- Mumbai
- Employees
- 607
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Supriya Lifescience in the last day or two.
Dividends and corporate actions
All companies- Dividend - Re 1 Per Share
Dividend · ex-date 4 September 2026
- Dividend - Re 1 Per Share
Dividend · ex-date 4 September 2025 · record date 5 September 2025
- Annual General Meeting/Dividend - Rs 0.80 Per Share
Dividend · ex-date 20 September 2024
- Annual General Meeting/Dividend - Re 0.60 Per Share
Dividend · ex-date 15 September 2023
- Annual General Meeting/Dividend - Re 0.60 Per Share
Dividend · ex-date 1 September 2022
Source: NSE. Latest first.
Information only, not investment advice. Prices are delayed.